Zurcher Kantonalbank Zurich Cantonalbank Boosts Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 123.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,578 shares of the specialty pharmaceutical company’s stock after buying an additional 14,679 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Jazz Pharmaceuticals were worth $3,273,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Jones Financial Companies Lllp boosted its position in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 176 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its position in shares of Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at $1,189,587.54. The trade was a 36.88 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Trading Up 1.4 %

Shares of JAZZ stock opened at $137.96 on Friday. The firm has a 50-day moving average price of $129.52 and a 200 day moving average price of $120.81. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on JAZZ shares. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. HC Wainwright boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Piper Sandler restated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.